FluoroPharma Medical (FluoroPharma Medical) Debt-to-Equity : -0.57 (As of Dec. 2016)

View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Debt-to-Equity?

FluoroPharma Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was $5.83 Mil. FluoroPharma Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was $0.00 Mil. FluoroPharma Medical's Total Stockholders Equity for the quarter that ended in Dec. 2016 was $-10.18 Mil. FluoroPharma Medical's debt to equity for the quarter that ended in Dec. 2016 was -0.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for FluoroPharma Medical's Debt-to-Equity or its related term are showing as below:

FPMI's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

FluoroPharma Medical Debt-to-Equity Historical Data

The historical data trend for FluoroPharma Medical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Debt-to-Equity Chart

FluoroPharma Medical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Debt-to-Equity

Get a 7-Day Free Trial

-0.44

-0.55

-0.57

FluoroPharma Medical Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
Debt-to-Equity	Get a 7-Day Free Trial															-0.55	-0.53	-0.53	-0.57	-0.57

Competitive Comparison of FluoroPharma Medical's Debt-to-Equity

For the Biotechnology subindustry, FluoroPharma Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FluoroPharma Medical's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Debt-to-Equity falls into.

FluoroPharma Medical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

FluoroPharma Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.825	+	0)	/	-10.179
	=	-0.57

FluoroPharma Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.825	+	0)	/	-10.179
	=	-0.57

FluoroPharma Medical (OTCPK:FPMI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

FluoroPharma Medical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

FluoroPharma Medical (FluoroPharma Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042

Website

http://www.fluoropharma.com

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Executives

Johan M. Spoor

director, officer: CEO, PRESIDENT, CHAIRMAN

500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus

FPMI Restructures CardioPET License With Massachusetts General Hospital

By Marketwired Marketwired • 09-27-2018